A multi-center retrospective study of Apatinib in patients with un-resectable high-grade osteosarcoma progressing after standard chemotherapy
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Rivoceranib (Primary)
- Indications Osteosarcoma
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2017 New trial record
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology